TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform..
Read More…
Industry, Sector and Symbol
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Phone+1-919-7658400
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable
TransEnterix (NYSEAMERICAN:TRXC) Frequently Asked Questions
What is TransEnterix's stock symbol?
TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."
How were TransEnterix's earnings last quarter?
TransEnterix, Inc. (NYSEAMERICAN:TRXC) posted its quarterly earnings data on Thursday, May, 9th. The medical instruments supplier reported ($0.09) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.09). The medical instruments supplier had revenue of $2.18 million for the quarter, compared to the consensus estimate of $4.50 million. View TransEnterix's Earnings History.
When is TransEnterix's next earnings date?
What price target have analysts set for TRXC?
4 brokerages have issued 12 month price objectives for TransEnterix's stock. Their forecasts range from $1.60 to $5.50. On average, they expect TransEnterix's share price to reach $3.7750 in the next year. This suggests a possible upside of 209.4% from the stock's current price. View Analyst Price Targets for TransEnterix.
What is the consensus analysts' recommendation for TransEnterix?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TransEnterix.
What are Wall Street analysts saying about TransEnterix stock?
Here are some recent quotes from research analysts about TransEnterix stock:
- 1. According to Zacks Investment Research, "TransEnterix Inc. designs, develops and manufactures medical-devices. It offers SPIDER(R) Surgical System, a laparoscopic surgical platform that allows intra-abdominal triangulation procedures to be performed with articulating instruments through a single site. The company is primarily focused on the development and commercialization of SurgiBot, a patient-side minimally invasive surgical robotic system. TransEnterix Inc., formerly known as SafeStitch Medical, Inc., is based in United States. " (6/14/2019)
- 2. BTIG Research analysts commented, "with TransEnterix announced the acquisition of MST Israeli company that has created an image analytics technology that uses artificial intelligence, scene recognition, and machine learning. With the cash + stock transaction (worth ~$33M as of 9/21 closing price) expected to close in Q4, TRXC will pick up the IP portfolio (30 patents, 31 pending), technology assets, and MST’s employees. Though the co’s AutoLap platform has FDA 510(k) and CE Mark clearance, TRXC does not intend to sell it as a standalone product. Instead, its capabilities— including dynamic 3D digital measurement, auto zoom, and anatomical structure identification—will be integrated into Senhance. Timing for these enhancements is unclear, though it is likely to take quarters, not years. We see this as an exciting step toward advanced digital laparoscopy, but our near-term focus remains on system sales." (9/25/2018)
Has TransEnterix been receiving favorable news coverage?
News headlines about TRXC stock have been trending neutral recently, according to InfoTrie. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TransEnterix earned a news impact score of 0.5 on InfoTrie's scale. They also assigned headlines about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for TransEnterix.
Who are some of TransEnterix's key competitors?
Some companies that are related to TransEnterix include Advanced Medical Solutions Group (AMS), Clover (CLV), CRH Medical (CRH), Bovie Medical (BVX), Bovie Medical (BVX), CRH Medical (CRHM), CRH Medical (CRHM), Tristel (TSTL), SDI (SDI), InfuSystem (INFU), G Medical (GMV), TSO3 (TOS), Daxor (DXR), IsoRay (ISR) and IsoRay (ISR).
What other stocks do shareholders of TransEnterix own?
Who are TransEnterix's key executives?
TransEnterix's management team includes the folowing people:
- Mr. Todd M. Pope, CEO, Pres & Director (Age 53)
- Mr. Joseph P. Slattery, Exec. VP, CFO & Principal Accounting Officer (Age 53)
- Mr. Anthony Fernando, COO, CTO & Exec. VP (Age 46)
- Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 45)
- Dr. Stephanie M. Fitts Ph.D., VP of RA/QA, Clinical and Compliance (Age 52)
Who are TransEnterix's major shareholders?
TransEnterix's stock is owned by a number of of retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (3.82%), First Trust Advisors LP (0.20%), Eagle Asset Management Inc. (0.17%), Alps Advisors Inc. (0.10%), Virtu Financial LLC (0.06%) and Enterprise Bank & Trust Co (0.04%). Company insiders that own TransEnterix stock include Anthony C J Fernando, Joseph P Slattery, Todd Pope, Willam N Kelley and William N Starling Jr. View Institutional Ownership Trends for TransEnterix.
Which major investors are selling TransEnterix stock?
TRXC stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, SG Americas Securities LLC and Eagle Asset Management Inc.. Company insiders that have sold TransEnterix company stock in the last year include Joseph P Slattery, Todd Pope and William N Starling Jr. View Insider Buying and Selling for TransEnterix.
Which major investors are buying TransEnterix stock?
TRXC stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Enterprise Bank & Trust Co, Alps Advisors Inc., Edmond DE Rothschild Holding S.A., BNP Paribas Arbitrage SA, Virtu Financial LLC, Whitnell & Co. and Steward Partners Investment Advisory LLC. View Insider Buying and Selling for TransEnterix.
How do I buy shares of TransEnterix?
Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TransEnterix's stock price today?
One share of TRXC stock can currently be purchased for approximately $1.22.
How big of a company is TransEnterix?
What is TransEnterix's official website?
How can I contact TransEnterix?
TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.
MarketBeat Community Rating for TransEnterix (NYSEAMERICAN TRXC)
MarketBeat's community ratings are surveys of what our community members think about TransEnterix and other stocks. Vote "Outperform" if you believe TRXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
